Loading…
Zimmer Biomet Holdings, Inc. is projected to rise to $123.18 by 2027, a +30% move from its current price of $94.96. ZBH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $93.24 | $95.00 | $96.80 | +0.05% |
| Aug 2 | $92.56 | $95.05 | $97.59 | +0.09% |
| Aug 3 | $92.06 | $95.09 | $98.22 | +0.14% |
| Aug 4 | $91.64 | $95.13 | $98.76 | +0.18% |
| Aug 5 | $91.28 | $95.17 | $99.24 | +0.23% |
| Aug 6 | $90.95 | $95.22 | $99.68 | +0.27% |
| Aug 7 | $90.66 | $95.26 | $100.09 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $90.66 | $95.26 | $100.09 | +0.32% |
| Week 2 | $89.10 | $95.56 | $102.49 | +0.63% |
| Week 3 | $87.99 | $95.87 | $104.45 | +0.95% |
| Week 4 | $87.11 | $96.17 | $106.18 | +1.27% |
| Week 5 | $86.37 | $96.47 | $107.77 | +1.59% |
| Week 6 | $85.73 | $96.78 | $109.25 | +1.92% |
| Week 7 | $85.17 | $97.09 | $110.67 | +2.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zimmer Biomet Holdings, Inc. operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.
products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues.
It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc.
and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Zimmer Biomet Holdings, Inc. is a medical technology company with a global footprint and a diverse portfolio of orthopedic reconstructive products, sports medicine and trauma solutions, and craniomaxillofacial and thoracic devices. Its ROSA Robot and ZBEdge Platform integrate robotic and digital technologies to support intraoperative decision-making and patient care.
The stock trades with a current price of $95.75 and a market cap of $18.52B, ranking it 602nd by market capitalization. The long‑term forecast landscape is bullish, with the average price expected to rise from $95.75 in 2026 to a peak average of $744.89 by 2050, and a max forecast reaching $1,217.61 in 2050, implying substantial upside over the coming years.
A major floor 16.7% below — a decisive break under it would weaken the trend.
The nearest floor, 11.4% below — buyers have tended to step in here.
Price is pressing into resistance (2.3% away) — a breakout level to watch.
A major ceiling 10.7% above — clearing it would confirm fresh momentum.
Key ZBH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZBH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $94.26 | Buy | $94.35 | Buy |
| MA 10 | $91.94 | Buy | $92.97 | Buy |
| MA 20 | $91.16 | Buy | $91.55 | Buy |
| MA 50 | $88.55 | Buy | $89.77 | Buy |
| MA 100 | $88.79 | Buy | $89.69 | Buy |
| MA 200 | $91.11 | Buy | $91.52 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.85 | Neutral |
| Stoch RSI (14) | 64.07 | Neutral |
| CCI (20) | 119.63 | Buy |
| Williams %R (14) | -25.86 | Info |
| MACD (12,26,9) | 0.50 | Buy |
| ROC (12) | 4.32 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 74.14 | Neutral |
| TRIX (15) | 0.18 | Buy |
| Awesome (5,34) | 4.19 | Buy |
| Ultimate (7,14,28) | 68.75 | Neutral |
| Momentum (10) | 1.21 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 97.08 | Sell |
| ADX (14) | 12.59 | Neutral |
| ATR (14) | 1.76 | Info |
Near term indicators point to a bullish tilt. The RSI14 sits at 60, and the stock trades above both the SMA50 of $87.65 and the SMA200 of $91.16, suggesting positive momentum. Key levels to watch are a support at $84.17 and a resistance at $94.08, with a 30‑day price range of $84.64 to $108.32.
The current sentiment aligns with ongoing upside potential in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $79.58 | $94.96 | $127.52 | 0% | Neutral | |
| $101.00 | $123.18 | $156.99 | +30% | Bullish | |
| $104.53 | $129.92 | $170.12 | +37% | Bullish | |
| $116.22 | $146.69 | $196.22 | +54% | Bullish | |
| $126.78 | $162.20 | $220.90 | +71% | Bullish | |
| $133.79 | $173.26 | $239.72 | +82% | Bullish | |
| $161.44 | $211.44 | $296.72 | +123% | Bullish | |
| $182.70 | $241.81 | $343.76 | +155% | Bullish | |
| $199.32 | $266.44 | $383.32 | +181% | Bullish | |
| $222.34 | $300.03 | $436.47 | +216% | Bullish | |
| $321.46 | $452.48 | $689.90 | +377% | Bullish | |
| $564.68 | $852.51 | $1,393.49 | +798% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $79.58 | $94.96 | $110.60 | +0.00% |
| August 2026 | $83.68 | $97.58 | $115.95 | +2.76% |
| September 2026 | $84.38 | $98.96 | $118.70 | +1.41% |
| October 2026 | $83.54 | $98.42 | $118.92 | -0.55% |
| November 2026 | $84.98 | $100.49 | $122.17 | +2.11% |
| December 2026 | $87.92 | $104.33 | $127.52 | +3.82% |
Click any year to see its month-by-month ZBH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Zimmer Biomet Holdings, Inc.'s 2026 outlook centres on $94.96, within a $79.58 to $127.52 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, ZBH could reach as high as $156.99, with a base case around $123.18 and support toward $101.00 — roughly +30% from $94.96. Momentum favours further upside here.
Expect ZBH to range from $104.53 to $170.12 through 2028. The $129.92 average target implies a +37% move from current prices. That is up +5% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The ZBH price prediction for 2029 points to an average of $146.69 (low $116.22, high $196.22) — a potential gain of +54% on today's $94.96. Momentum favours further upside here.
In 2030, ZBH is projected to trade between $126.78 and $220.90, averaging $162.20 — a potential gain of +71% from today's $94.96. That is up +11% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Zimmer Biomet Holdings, Inc.'s 2031 outlook centres on $173.26, within a $133.79 to $239.72 range. That is up +7% on the projected 2030 average. That marks a +82% change versus current levels. Momentum favours further upside here.
By 2032, ZBH could reach as high as $296.72, with a base case around $211.44 and support toward $161.44 — roughly +123% from $94.96. Buyers look set to stay in control over this stretch.
Expect ZBH to range from $182.70 to $343.76 through 2033. The $241.81 average target implies a +155% move from current prices. That is up +14% on the projected 2032 average. Momentum favours further upside here.
The ZBH price prediction for 2034 points to an average of $266.44 (low $199.32, high $383.32) — a potential gain of +181% on today's $94.96. Buyers look set to stay in control over this stretch.
In 2035, ZBH is projected to trade between $222.34 and $436.47, averaging $300.03 — a potential gain of +216% from today's $94.96. That is up +13% on the projected 2034 average. Momentum favours further upside here.
Zimmer Biomet Holdings, Inc.'s 2040 outlook centres on $452.48, within a $321.46 to $689.90 range. That is up +51% on the projected 2035 average. That marks a +377% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, ZBH could reach as high as $1,393.49, with a base case around $852.51 and support toward $564.68 — roughly +798% from $94.96. Momentum favours further upside here.
Investing $1,000 in ZBH today (≈ 10.53075 ZBH) could be worth
$8,977.57
+$7,977.57 (+798%) by 2050 · US Dollar
Based on the average projected ZBH price of $852.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZBHwould be worth at today's price.
$1,000 invested in ZBH on Jul 30, 2025 (≈ 10.715817 ZBH) would be worth
$1,017.57
+$17.57 (+1.8%) today · 1.02× · US Dollar
Based on a ZBH entry price of $93.32 vs. today's $94.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $89.65 | $1,059.23 | +5.9% |
| 1 month ago | $86.09 | $1,103.03 | +10.3% |
| 3 months ago | $82.9 | $1,145.48 | +14.5% |
| 6 months ago | $87.07 | $1,090.62 | +9.1% |
| 1 year ago | $93.32 | $1,017.57 | +1.8% |
| All time (5.0y) ago | $158.26 | $600.02 | -40.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZBH forecast.
Our base-case forecast reaches $190.00 around 2032.
Implied market cap at $190.00: $36.76B
The multi‑year forecast depicts a strong upward trajectory. By 2030 the average forecast is $154.90 with a min of $121.07 and a max of $210.98, yielding an estimated ROI of 61.8% and a bullish sentiment. By 2040 the average is $402.94 and the max $614.39, with an ROI of 320.8% and continued bullish trend.
By 2050 the average is $744.89 and the max $1,217.61, with an ROI of 678% and a sustained bullish outlook. The trajectory suggests meaningful long‑term upside, but these figures are estimates and carry inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $154.90 with a min of $121.07 and a max of $210.98, and an estimated ROI of 61.8% with a bullish sentiment.
The forecast displays a bullish sentiment from 2027 onward, with the average price rising to $122.04 in 2027 and higher through 2030 ($154.90), 2040 ($402.94), and 2050 ($744.89), and ROIs up to 678% by 2050. These are estimates and not guarantees.
Yes. The forecasted maximum prices include 2033 at $317.92 and 2034 at $353.81, indicating the potential to surpass $300 in the mid‑2030s.
The current price is $95.75 and the market cap is $18.52B.
By 2040 the average is $402.94 with a max of $614.39 and an ROI of 320.8%. By 2050 the average is $744.89 with a max of $1,217.61 and an ROI of 678%.
Zimmer Biomet Holdings, Inc. Community Discussion
0Share your Zimmer Biomet Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.